Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk

Boziki, Marina; Karapanayotides, Theodoros; Papadopoulos, Georgios; Lagoudaki, Roza; Melo, Pamela; Bakirtzis, Christos; Nikolaidis, Ioannis; Gounari, Evdoxia; Tsavdaridou, Vasiliki; Skoura, Lemonia; Afrantou, Theodora; Tatsi, Theano; Grigoriadou, Eleni; Polyzoidou, Eleni; Mandoras, Nikolaos; Giantzi, Virginia; Kalogera‐Fountzila, Anna; Ioannidis, Panagiotis; Parissis, Dimitrios; Pelidou, Sygkliti-Henrietta; Zoidou, Sofia; Grigoriadis, Nikolaos

doi:10.1080/01616412.2020.1722913

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our experience, access to the essential genetic testing procedures, where necessary, is crucial for the management of degenerative dementias [ 18 , 19 , 20 , 21 ] and other rare diseases such as neuromuscular [ 22 , 23 ], inflammatory and autoimmune [ 24 , 25 , 26 , 27 , 28 , 29 ], peripheral neuropathies [ 24 , 30 ] and cerebrovascular rare diseases [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background and Objectives: Rare diseases (RDs) are life-threatening or chronically impairing conditions that affect about 6% of the world’s population. RDs are often called ‘orphan’ diseases, since people suffering from them attract little support from national health systems. Aim: The aim of this study is to describe the clinical characteristics of, and the available laboratory examinations for, patients who were hospitalized in a tertiary referral center and finally received a diagnosis associated with a Rare Neurological Disease (RND). Materials and Methods: Patients that were hospitalized in our clinic from 1 January 2014 to 31 March 2022 and were finally diagnosed with an RND were consecutively included. The RND classification was performed according to the ORPHAcode system. Results: A total of 342 out of 11.850 (2.9%) adult patients admitted to our department during this period received a diagnosis associated with an RND. The most common diagnosis (N = 80, 23%) involved an RND presenting with dementia, followed by a motor neuron disease spectrum disorder (N = 64, 18.7%). Family history indicative of an RND was present in only 21 patients (6.1%). Fifty-five (16%) people had previously been misdiagnosed with another neurological condition. The mean time delay between disease onset and diagnosis was 4.24 ± 0.41 years. Conclusions: Our data indicate that a broad spectrum of RNDs may reach a tertiary Neurological Center after a significant delay. Moreover, our data underline the need for a network of reference centers, both at a national and international level, expected to support research on the diagnosis and treatment of RND.

show abstract

Section: Discussionmentioning

confidence: 99%

The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…These patients achieved long-standing clinical and radiological remission under NTZ. One seropositive patient developed PML shortly after NTZ discontinuation was suggested and PML was diagnosed at a pre-symptomatic phase on a routine MRI ( 35 ). In the FTY-treated group, treatment inefficacy and lymphopenia were the main reasons for treatment discontinuation.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Boziki¹,

Bakirtzis²,

Giantzi³

et al. 2021

Front. Neurol.

Self Cite

View full text Add to dashboard Cite

Background: Natalizumab (NTZ) and fingolimod (FTY) are second-line disease modifying treatments (DMTs) approved for Relapsing – Remitting Multiple Sclerosis (RRMS). Few studies are available on a direct comparison between NTZ and FTY, based on post-marketing experience, with conflicting results and reporting relatively short follow-up period.Aim: We hereby report real-world experience of a MS Center with respect to NTZ vs. FTY comparison in terms of efficacy and safety, referencing long-term follow-up.Methods: We used retrospective data for all patients that received 2nd-line treatment NTZ (since May 2007) or FTY (since September 2011). Primary endpoints were, among others, annual EDSS score (mean change from baseline), time to disability worsening or improvement, Annualized Relapse Rate (ARR) after 12 and 24 months and upon total treatment duration, time to first relapse and time to radiological progression.Results: A total of 138 unmatched patients, 84 treated with NTZ and 54 treated with FTY were included. Following Propensity Score (PS) matching, 31 patients in each group were retained. Mean follow-up period for NTZ- and FTY-treated patients was 4.43 ± 0.29 and 3.59 ± 0.32 years (p = 0.057), respectively. In the matched analysis, time to disability improvement and time to disability worsening was comparable between groups. A higher proportion of patients remained free of relapse under NTZ, compared to FTY (Log Rank test p = 0.021, HR: 0.25, 95% CI: 0.08–0.8), as well as free of MRI activity (Log Rank test p = 0.006, HR: 0.26, 95% CI: 0.08–0.6). Treatment discontinuation due to MRI activity was significantly higher for FTY-treated patients compared to NTZ (Log Rank test p = 0.019, HR: 0.12, 95% CI: 0.05–0.76).Conclusion: Our results indicate toward NTZ superiority with respect to relapse and MRI activity outcomes. The fact that NTZ-treated patients may achieve long-standing clinical and radiological remission points toward the need for long follow-up data.

show abstract

Natalizumab

2020

Reactions Weekly

View full text Add to dashboard Cite

Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk

Cited by 6 publications

References 33 publications

The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases

The Experience of a Tertiary Reference Hospital in the Study of Rare Neurological Diseases

Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center

Natalizumab

Contact Info

Product

Resources

About